Literature DB >> 11163182

An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity.

R Majeti1, Z Xu, T G Parslow, J L Olson, D I Daikh, N Killeen, A Weiss.   

Abstract

A model has been proposed for the regulation of CD45, and by homology other RPTPs, in which dimerization inhibits phosphatase activity through symmetrical interactions between an inhibitory structural wedge and the catalytic site. Here, we report the phenotype of mice with a single point mutation, glutamate 613 to arginine, that inactivates the inhibitory wedge of CD45. The CD45 E613R mutation causes polyclonal lymphocyte activation leading to lymphoproliferation and severe autoimmune nephritis with autoantibody production, resulting in death. Both homozygotes and heterozygotes develop pathology, indicating genetic dominance of CD45 E613R. The dramatic phenotype of CD45 E613R mice demonstrates the in vivo importance of negative regulation of CD45 by dimerization, supporting the model for regulation of CD45, and RPTPs in general.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163182     DOI: 10.1016/s0092-8674(00)00209-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  63 in total

Review 1.  Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.

Authors:  Michelle L Hermiston; Zheng Xu; Ravindra Majeti; Arthur Weiss
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

Review 3.  Positive and negative regulation of T-cell activation through kinases and phosphatases.

Authors:  Tomas Mustelin; Kjetil Taskén
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

4.  Preferential oxidation of the second phosphatase domain of receptor-like PTP-alpha revealed by an antibody against oxidized protein tyrosine phosphatases.

Authors:  Camilla Persson; Tobias Sjöblom; Arnoud Groen; Kai Kappert; Ulla Engström; Ulf Hellman; Carl-Henrik Heldin; Jeroen den Hertog; Arne Ostman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

5.  Dimerization in vivo and inhibition of the nonreceptor form of protein tyrosine phosphatase epsilon.

Authors:  Hila Toledano-Katchalski; Zohar Tiran; Tal Sines; Gidi Shani; Shira Granot-Attas; Jeroen den Hertog; Ari Elson
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 6.  Genetics of SLE in mice.

Authors:  Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

7.  Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production.

Authors:  Robyn E Mills; Viola C Lam; Allison Tan; Nicole Cresalia; Nir Oksenberg; Julie Zikherman; Mark Anderson; Arthur Weiss; Michelle L Hermiston
Journal:  J Immunol       Date:  2015-03-13       Impact factor: 5.422

Review 8.  Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.

Authors:  Julie Zikherman; Michelle Hermiston; David Steiner; Kiminori Hasegawa; Andrew Chan; Arthur Weiss
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 10.  CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells.

Authors:  Michelle L Hermiston; Julie Zikherman; Jing W Zhu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.